<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329769</url>
  </required_header>
  <id_info>
    <org_study_id>PRO044-CLIN-02</org_study_id>
    <nct_id>NCT02329769</nct_id>
  </id_info>
  <brief_title>Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A Phase II, Open Label, Extension Study to Assess the Effect of PRO044 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether PRO044 is safe and effective to use as medication
      for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 44 in the DNA
      for the dystrophin protein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, open-label, extesion study. Following a Screening period of up to one month,
      subjects previously treated with PRO044, and eligible for enrolment in PRO044-CLIN-02, will
      be allocated to one of three groups to receive either 6 mg/kg or 9 mg/kg PRO044 weekly by IV
      infusion or 6 mg/kg weekly by SC injection for 48 weeks.

      Safety and tolerability, pharmacokinetics (PK), pharmacodynamic (PD) and efficacy assessments
      will be conducted at regular intervals throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">July 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of PRO044 (composite of several measures)</measure>
    <time_frame>After 48 weeks of treatment</time_frame>
    <description>Efficacy parameters:
Muscle Function
6 Minute Walk Distance (6MWD)
North Star Ambulatory Assessment
Timed tests (10-meter walk/run, rising from floor, stair climb)
DMD Functional Outcomes Questionnaire (DMD-FOS) -for ambulant subjects only
Egen Klassification - for non-ambulant subjects.
Muscle strength
Pulmonary Function (Spirometry)
Handheld myometry.
Exploratory:
Performance Upper Limb (PUL).
Patient Reported Outcome measure (PROM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of PRO044 (treatement emergent adverse events)</measure>
    <time_frame>After 48 weeks of treatment</time_frame>
    <description>Number of subjects with 1 or more treatement emergent adverse events following SC or IV PRO044 dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetics of PRO044 (composite of several measures)</measure>
    <time_frame>After 48 weeks of treatment</time_frame>
    <description>Pharmacokinetic parameters:
t ½
AUC: 0-24h, 0-∞ (where applicable)
Cmax
tmax
CL (for IV subjects) or CL/F (for SC subjects)
PRO044 concentrations in muscle tissue.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>PRO044 SC 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly subcutaneous (SC) dosing with 6 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO044 IV 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly intravenous (IV) dosing with 6 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO044 SC 9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly intravenous (IV) dosing with 9 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO044 SC 6 mg/kg</intervention_name>
    <arm_group_label>PRO044 SC 6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO044 IV 6 mg/kg</intervention_name>
    <arm_group_label>PRO044 IV 6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO044 IV 9 mg/kg</intervention_name>
    <arm_group_label>PRO044 SC 9 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects previously treated with PRO044.

          2. Continued use of glucocorticoids for a minimum of 60 days prior to study entry with a
             reasonable expectation that the subject will remain on steroids for the duration of
             the study. Changes to the dose regimen or cessation of glucocorticoids will be at the
             discretion of the Principle Investigator (PI) in consultation with the subject/parent
             and the Medical Monitor. If the subject is not on steroids, involvement in the study
             needs to be discussed with the medical monitor

        Exclusion Criteria:

          1. Current, or history of, liver or renal disease.

          2. Acute illness within 4 weeks prior to the first dose of PRO044 (Week 1) which may
             interfere with the measurements.

          3. Severe cardiac myopathy which in the opinion of the Investigator prohibits
             participation in this study

          4. Need for daytime mechanical ventilation.

          5. Screening aPTT above the upper limit of normal (ULN).

          6. Screening platelet count below the lower limit of normal (LLN).

          7. Use of anticoagulants, antithrombotics or antiplatelet agents.

          8. Use of any investigational product within 6 months prior to the start of Screening for
             the study.

          9. Current or history of drug and/or alcohol abuse.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.Anna Hospital</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn- ochungdomssjukhus</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>BioMarin</keyword>
  <keyword>PRO044</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

